Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	26.05	21.41	14.25
Research & Development	129.03	100.64	81.01
Operating Expenses	155.08	122.05	95.26
Operating Income	-155.08	-122.05	-95.26
Interest Expense	-	-	-1.6
Interest & Investment Income	22.18	16.63	6.4
Other Non Operating Income (Expenses)	0.01	-0.01	0
EBT Excluding Unusual Items	-132.89	-105.43	-90.46
Other Unusual Items	-	-	-0.87
Pretax Income	-132.89	-105.43	-91.34
Net Income	-132.89	-105.43	-91.34
Preferred Dividends & Other Adjustments	-23.2	-21.12	-20.39
Net Income to Common	-109.69	-84.31	-70.95
Net Income Growth	-	-	-
Shares Outstanding (Basic)	54	46	17
Shares Outstanding (Diluted)	54	46	17
Shares Change	49.96%	171.69%	-
EPS (Basic)	-2.02	-1.85	-4.23
EPS (Diluted)	-2.02	-1.85	-4.23
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-101.15	-88.42	-63.3
Free Cash Flow Per Share	-1.87	-1.94	-3.77
EBITDA	-154.94	-121.97	-95.23
D&A For EBITDA	0.13	0.08	0.03
EBIT	-155.08	-122.05	-95.26

SEC Filings: 10-K · 10-Q